Regeneron Pharmaceuticals, Inc. (REGN) Stock: A Look at the Analyst Recommendations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a higher price-to-earnings ratio of 26.48x compared to its average ratio. REGN has 36-month beta value of 0.15. Analysts